Research ArticleOpen AccessGoogle Scholar indexed

ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?

¹ The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
³ The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel
⁴ The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel
⁵ Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
⁶ The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel
⁷ Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
⁸ The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel
⁹ The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel
¹⁰ The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel

Journal of Cancer Therapy·Volume 11 (2020)·Pages 365–370·Published 29 May 2020·DOI10.4236/jct.2020.116031

Abstract

ROS1 oncogenic fusion is reported to be 1% - 2% of non-small cell lung cancers (NSCLCs) of the adenocarcinoma subgroup. Meanwhile, there are no records of squamous cell cancer patients with tumors harboring ROS1 fusions. The Foundation Medicine database indicates a frequency of ROS1 rearrangements is 0.2% among squamous NSCLC. Crizotinib is known to be very effective in these patients . Here we present a non-smoker patient who had pure squamous NSCLC that was treated by combinational immunotherapy under a clinical trial and progressed after 2 cycles. Surprisingly, comprehensive genomic profiling detected a rare oncogenic EZR-ROS1 fusion, and the patient was treated by crizotinib with a significant response within 6 weeks. To date, the patient has been on therapy for 42 months and has achieved a complete metabolic response.

KeywordsROS1CrizotinibSquamous Cell Lung CancerImmunotherapyNon-Small Cell Lung Cancer

Lin, J.J., Ritterhouse, L.L., Ali, S.M., et al. (2017) ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 12, 872-877. https://doi.org/10.1016/j.jtho.2017.01.004
Zhao, W., Choi, Y.L., Song, J.Y., et al. (2016) ALK, ROS1 and RET Rearrangements in Lung Squamous Cell Carcinoma Are Very Rare. Lung Cancer, 94, 22-27. https://doi.org/10.1016/j.lungcan.2016.01.011
Shaw, A.T., Ou, S.H.I., Bang, Y.J., et al. (2014) Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer [Internet]. New England Journal of Medicine, 371, 1963-1971. http://www.nejm.org/doi/abs/10.1056/NEJMoa1406766
Facchinetti, F. and Friboulet, L. (2018) Lorlatinib in ALK- and ROS1-Positive NSCLC: The Future Has a Start. Translational Lung Cancer Research, 7, S103-S106. https://doi.org/10.21037/tlcr.2018.02.04
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2019) Updated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. https://doi.org/10.1200/jco.18.00149
(2018) Pembrolizumab plus Chemotherapy in Lung Cancer [Internet]. New England Journal of Medicine, 379, e18. http://www.nejm.org/doi/10.1056/NEJMc1808567
Paz-Ares, L., Luft, A., Vicente, D., et al. (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [Internet]. New England Journal of Medicine, 379, 2040-2051. http://www.nejm.org/doi/10.1056/NEJMoa1810865 https://doi.org/10.1056/nejmoa1810865
Reck, M., Schenker, M., Lee, K.H., et al. (2019) Nivolumab plus Ipilimumab versus Chemotherapy as First-Line Treatment in Advanced Non-Small-Cell Lung Cancer with High Tumour Mutational Burden: Patient-Reported Outcomes Results from the Randomised, Open-Label, Phase III CheckMate 227 Trial. European Journal of Cancer, 116, 137–147. https://doi.org/10.1016/j.ejca.2019.05.008
Lisberg, A., Cummings, A., Goldman, J.W., et al. (2018) A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients with Advanced NSCLC [Internet]. Journal of Thoracic Oncology, 13, 1138-1145. http://www.ncbi.nlm.nih.gov/pubmed/29874546 https://doi.org/10.1016/j.jtho.2017.09.456

Menu

Menu

Menu

ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?

Abstract

References (9)